Yu Cao

5.1k total citations · 1 hit paper
88 papers, 2.9k citations indexed

About

Yu Cao is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Yu Cao has authored 88 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Molecular Biology, 31 papers in Oncology and 20 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Yu Cao's work include Monoclonal and Polyclonal Antibodies Research (20 papers), CAR-T cell therapy research (18 papers) and Cancer-related molecular mechanisms research (8 papers). Yu Cao is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (20 papers), CAR-T cell therapy research (18 papers) and Cancer-related molecular mechanisms research (8 papers). Yu Cao collaborates with scholars based in China, United States and South Korea. Yu Cao's co-authors include Lijun Zhao, Peter G. Schultz, Zhidong Wang, Chan Hyuk Kim, Travis S. Young, Timothy M. Wright, David T. Rodgers, Feng Wang, Stephanie A. Kazane and Seihyun Choi and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Nucleic Acids Research.

In The Last Decade

Yu Cao

84 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Engineered T Cell Therapy for Cancer in the Clinic

2019 295 citations Lijun Zhao, Yu Cao Frontiers in Immunology profile →

Peers

Countries citing papers authored by Yu Cao

Since Specialization

Citations

This map shows the geographic impact of Yu Cao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu Cao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu Cao more than expected).

Fields of papers citing papers by Yu Cao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu Cao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu Cao. The network helps show where Yu Cao may publish in the future.

Co-authorship network of co-authors of Yu Cao

This figure shows the co-authorship network connecting the top 25 collaborators of Yu Cao. A scholar is included among the top collaborators of Yu Cao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu Cao. Yu Cao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Detection of quantitative trait nucleotides (QTNs) and QTN-by-environment and QTN-by-QTN interactions for cotton early-maturity traits using the 3VmrMLM method 2024 ·Industrial Crops and Products ·Chengqi Li, (unknown), Xin Gao, Yu Cao, (unknown), (unknown), Lei Du, (unknown), Yong-hong Zhu, Huanyang Zhang, Fuli Li, (unknown), (unknown), (unknown), Juan Wang	1
2	Systemic inflammatory regulators and age-related macular degeneration: a bidirectional Mendelian randomization study 2024 ·Frontiers in Genetics ·Xi Liu, Yu Cao, Ying Wang, Lihua Kang, Guowei Zhang, (unknown), Bai Qin, Ling Yang, (unknown), Pengfei Li, (unknown), Min Ji, Huaijin Guan	1
3	Targeted Lipid Nanoparticle Delivery of an RNA Gene Writer In Vivo Enables Generation of CAR-T Cells in a Humanized Mouse Model 2024 ·Blood ·(unknown), Alberto De Iaco, James B. Rottman, Donghui Liu, (unknown), Xin Qiao, Yu Cao, (unknown), Mohit Gupta, Rahul Palchaudhuri, (unknown), Cecilia Cotta‐Ramusino, Hari Pujar, Madhusudan V. Peshwa, Michael C. Holmes	2
4	The m6A regulators in prostate cancer: molecular basis and clinical perspective 2024 ·Frontiers in Pharmacology ·Yu Cao, (unknown), Chunyan Duan, Zhihui Yang, Bo Cheng, Ronghao Wang	1
5	Transcriptome and metabolome profiling unveil the accumulation of chlorogenic acid in autooctoploid Gongju 2024 ·Frontiers in Plant Science ·Li Zhao, Yu Cao, (unknown), Jiayi Zhou, Xintong Li, Peng Liu, (unknown), (unknown), Ri Gao	3
6	Allosteric autoregulation of DNA binding via a DNA-mimicking protein domain: a biophysical study of ZNF410–DNA interaction using small angle X-ray scattering 2023 ·Nucleic Acids Research ·Gundeep Kaur, Ren Ren, Michal Hammel, J.R. Horton, Jie Yang, Yu Cao, Chenxi He, Fei Lan, Xianjiang Lan, Gerd A. Blobel, Robert Blumenthal, Xing Zhang, Xiaodong Cheng	8
7	Deploying an RNA-Based Gene Writer System and Lipid Nanoparticle (LNP) Delivery to Generate Functional Chimeric Antigen Receptor (CAR) T Cells with in Vitro and In Vivo Anti-Tumor Activity 2023 ·Blood ·Michael S. Magee, Alberto De Iaco, (unknown), James B. Rottman, Donghui Liu, Giulia Schiroli, Pooja Sabhachandani, Yu Cao, (unknown), Mohit Gupta, (unknown), Jane Wang, (unknown), Cecilia Cotta‐Ramusino, Madhusudan V. Peshwa, Michael C. Holmes	3
8	Cuproptosis-Related MiR-21-5p/FDX1 Axis in Clear Cell Renal Cell Carcinoma and Its Potential Impact on Tumor Microenvironment 2022 ·Cells ·(unknown), Bo Cheng, Shuang Yu, (unknown), Yu Cao, Tiejun Zhou, Kun Han, Rongyang Dai, (unknown)	48
9	Synthesis of precision antibody conjugates using proximity-induced chemistry 2021 ·Theranostics ·Yu Cao, Chenfei Yu, Kuan‐Lin Wu, Xuechun Wang, Dong Liu, Zeru Tian, Lijun Zhao, (unknown), Axel Loredo, (unknown), Han Xiao	30
10	Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research 2020 ·Frontiers in Immunology ·Zhidong Wang, Yu Cao	138
11	Photochemical activation of MH3-B1/rGel: a HER2-targeted treatment approach for ovarian cancer 2015 ·Oncotarget ·(unknown), (unknown), Kristian Berg, Yu Cao, Ellen Skarpen, (unknown), Michael G. Rosenblum, Qian Peng, Anette Weyergang	16
12	Two distinct and competitive pathways confer the cellcidal actions of artemisinins 2015 ·Microbial Cell ·(unknown), (unknown), Yu Cao, (unknown), Bing Zhou	20
13	Development of Human Serine Protease-Based Therapeutics Targeting Fn14 and Identification of Fn14 as a New Target Overexpressed in TNBC 2014 ·Molecular Cancer Therapeutics ·Hong Zhou, Khalid A. Mohamedali, Ana M. González-Angulo, Yu Cao, Mary Migliorini, Lawrence H. Cheung, Janine LoBello, Xiudong Lei, Yuan Qi, Walter N. Hittelman, Jeffrey A. Winkles, Nhan L. Tran, Michael G. Rosenblum	21
14	Photochemical activation of the recombinant HER2-targeted fusion toxin MH3-B1/rGel; Impact of HER2 expression on treatment outcome 2014 ·Journal of Controlled Release ·(unknown), Yu Cao, Kristian Berg, Ellen Skarpen, Michael G. Rosenblum, Anette Weyergang	19
15	The Functionalized Human Serine Protease Granzyme B/VEGF121 Targets Tumor Vasculature and Ablates Tumor Growth 2013 ·Molecular Cancer Therapeutics ·Khalid A. Mohamedali, Yu Cao, Lawrence H. Cheung, Walter N. Hittelman, Michael G. Rosenblum	12
16	EGFR-Induced and PKCε Monoubiquitylation-Dependent NF-κB Activation Upregulates PKM2 Expression and Promotes Tumorigenesis 2012 ·Molecular Cell ·Weiwei Yang, Yan Xia, Yu Cao, Yanhua Zheng, Wen Bu, Lin Zhang, M. James You, Mei Yee Koh, Gilbert J. Cote, Kenneth Aldape, Yi Li, Inder M. Verma, Paul J. Chiao, Zhimin Lu	219
17	Cell-Targeting Fusion Constructs Containing Recombinant Gelonin 2011 ·Methods in enzymology on CD-ROM/Methods in enzymology ·Mi-Ae Lyu, Yu Cao, Khalid A. Mohamedali, Michael G. Rosenblum	23
18	Single-Chain Antibody-Based Immunotoxins Targeting Her2/neu: Design Optimization and Impact of Affinity on Antitumor Efficacy and Off-Target Toxicity 2011 ·Molecular Cancer Therapeutics ·Yu Cao, James D. Marks, Qian Huang, Stephen I. Rudnick, Chiyi Xiong, Walter N. Hittelman, Xiaoxia Wen, John W. Marks, Lawrence H. Cheung, (unknown), Chun Li, Gregory P. Adams, Michael G. Rosenblum	54
19	Construction and Characterization of Novel, Recombinant Immunotoxins Targeting the Her2/neu Oncogene Product: In vitro and In vivo Studies 2009 ·Cancer Research ·Yu Cao, James D. Marks, John W. Marks, Lawrence H. Cheung, Sehoon Kim, Michael G. Rosenblum	43
20	[Experimental studies on the apoptosis of HL-60 cells induced by Brucea javanica oil emulsion]. 2003 ·PubMed ·Fang Wang, Yu Cao, Hongyan Liu, Zhao-Di Fu, Rui Han	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact